Advances in Hematology Q3
Unclaimed
Advances in Hematology is a journal indexed in SJR in Hematology with an H index of 38. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 697,5 €. The scope of the journal is focused on lymphoma, erythrocytes, haematology, leukaemia. It has an SJR impact factor of 0,553 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,553.
Type: Journal
Type of Copyright: CC BY
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -
697,5 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
0,553
SJR Impact factor38
H Index8
Total Docs (Last Year)44
Total Docs (3 years)213
Total Refs68
Total Cites (3 years)44
Citable Docs (3 years)1.37
Cites/Doc (2 years)26.63
Ref/DocOther journals with similar parameters
Clinical Lymphoma, Myeloma and Leukemia Q3
Lymphology Q3
Hematology Q3
Journal of Blood Medicine Q3
Mediterranean Journal of Hematology and Infectious Diseases Q3
Compare this journals
Aims and Scope
Best articles by citations
Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
View moreCurrent Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
View moreComplex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia
View moreFlow Cytometric Detection of the Classical Hodgkin Lymphoma: Clinical and Research Applications
View morePrognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography
View morePractical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
View moreDevelopment and Characterization of Anti-Nitr9 Antibodies
View moreGene Expression Profiling forIn SilicoMicrodissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features
View moreHairy Cell Leukemia and Bladder Cancer in a Patient: Relation with Dye Exposure and Review of the Literaure
View moreChimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
View moreImproving TCR Gene Therapy for Treatment of Haematological Malignancies
View moreRelative Susceptibilities of ABO Blood Groups toPlasmodium falciparumMalaria in Ghana
View moreBiochemical Markers of Bone Turnover in Patients withbeta-Thalassemia Major: A Single Center Study from Southern Pakistan
View moreThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
View moreImpaired Fibrinolysis in Angiographically Documented Coronary Artery Disease
View moreInterim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
View morePrevalence and Specificity of RBC Alloantibodies in Indian Patients Attending a Tertiary Care Hospital
View moreTreatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
View moreThe Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
View moreEthical and Clinical Aspects of Intensive Care Unit Admission in Patients with Hematological Malignancies: Guidelines of the Ethics Commission of the French Society of Hematology
View moreUnanswered Questions in HIV Hematology
View moreHepcidin: A Critical Regulator of Iron Metabolism during Hypoxia
View moreSynergistic Effect of Anemia and Red Blood Cells Transfusion on Inflammation and Lung Injury
View moreEngineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
View more
Comments